Dasan AT Invests 120 Billion Won in Gumi's New Factory to Expand RF Micro Needle Production for K-Beauty Growth

South Korean company DASAN AT has completed the construction of a new facility at Gumi National Industry Complex, marking a strategic expansion into the production of advanced medical devices. The 120 billion won investment, announced in 2025, includes the establishment of a state-of-the-art manufacturing site focused on RF micro needles—precision medical tools used in dermatological treatments and minimally invasive procedures. The project is expected to create over 60 new jobs, signaling a shift in Gumi’s industrial landscape toward high-tech healthcare innovation.

What Happened

DASAN AT, originally a semiconductor parts manufacturer, has expanded its operations to produce RF micro needles, which deliver high-frequency energy to stimulate collagen production and improve skin texture. The new facility, inaugurated on May 30, 2026, is designed to meet growing global demand for non-surgical aesthetic and therapeutic treatments. The company, which began as Dasan Jeonggong in 1998, has gradually transitioned from industrial components to medical device manufacturing, with a focus on precision-engineered products like hair transplant needles and RF-based medical tools.

Why It Matters

The expansion aligns with the rising popularity of K-Beauty and non-invasive medical aesthetics, which have driven demand for advanced, locally produced technologies. By establishing a dedicated manufacturing hub in Gumi, DASAN AT aims to strengthen South Korea’s position in the global medical device market while addressing the need for domestic production of specialized components. The project also reflects broader efforts to diversify Gumi’s industrial base, which has historically been centered on semiconductors and electronics.

What May Happen Next

Industry analysts suggest that DASAN AT’s move could prompt further investment in medical technology within Gumi’s industrial zones. The company’s focus on RF micro needles—used in both cosmetic and therapeutic applications—may attract partnerships with international healthcare firms seeking reliable suppliers. However, the long-term success of the initiative will depend on global market dynamics, regulatory approvals and the company’s ability to scale production while maintaining quality standards.

Did You Know? DASAN AT’s new facility is part of a broader trend in Gumi, where over 49.9 billion won is planned for defence and industrial innovation projects by 2027, including specialized research infrastructure and workforce development.

Expert Insight: The shift of a semiconductor-focused firm into medical device manufacturing highlights the potential for cross-industry innovation. By leveraging existing technical expertise, DASAN AT could bridge gaps in South Korea’s healthcare supply chain, though challenges like international competition and rapid technological changes remain critical factors.

Frequently Asked Questions

What is the primary focus of DASAN AT’s new facility?

The facility specializes in producing RF micro needles, which are used in dermatological treatments to stimulate collagen production and improve skin texture.

Frequently Asked Questions — Micro Needle Production Billion Won

How much investment was allocated for the new facility?

DASAN AT invested a total of 120 billion won, as part of a 2025 agreement with Gumi City, to establish the new manufacturing site.

What role does Gumi National Industry Complex play in this expansion?

The complex serves as a strategic hub for industrial innovation, with DASAN AT’s expansion contributing to the region’s diversification into high-tech medical manufacturing.

How might this development influence the future of medical technology in South Korea? Share your thoughts below.

Dasan AT Invests 120 Billion Won in Gumi’s New Factory to Expand RF Micro Needle Production for K-Beauty Growth